Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
64,221.79 -2,115.95 (-3.19%) CMC Crypto 200
1,385.35 -38.75 (-2.72%)
Biogen Inc. (BIIB)
After hours:
| Previous close | 193.18 |
| Open | 199.18 |
| Bid | 201.78 x 100 |
| Ask | 202.03 x 100 |
| Day's range | 198.97 - 205.75 |
| 52-week range | 189.44 - 319.76 |
| Volume | |
| Avg. volume | 1,201,566 |
| Market cap | 29.361B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 25.31 |
| EPS (TTM) | 7.98 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 297.80 |
- Yahoo Finance Video
Biogen stock rises on Q1 results, Alzheimer's drug sales
Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter results. The company beat profit expectations, driven by Biogen's cost-cutting initiatives and the boost in sales for its Alzheimer's drug, Leqembi. Yahoo Finance's Anjalee Khemlani breaks down the details of the report. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
BenzingaBiogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
On Wednesday, Biogen Inc (NASDAQ:BIIB) reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The company reported sales of $2.29 billion, down 7% year over year and missing the consensus of $2.31 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431.3 million from $472.8 million. Also Read: Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analys
ZacksBiogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
